News

Report Shows Diabetes Drug Best Sellers

“Top 100 Selling Drugs Through September,” an article in the October 31 issue of Medscape (sourced from IMS Health), shows that while eight diabetes medications are in the nation’s top 100 best-selling drugs, none are in the top 10.

The report tracked sales and prescription numbers for the top drugs from October 1, 2012 through September 30, 2013.

The eight drugs named below are listed according to the number of their position in the sales rankings and their total dollar sales:

14. Januvia, $2.825 billion

15. Lantus Solostar: $2.779 billion

18. Lantus: $2.515 billion

34. Novolog: $1.33 billion

35. Novolog Flexpen: $1.317 billion

39. Humalog: $1.143 billion

47. Janument: $967 million

90. Actos: $130 million

Prescription Numbers

The report also ranked the top 100 drugs by number of prescriptions over the same one-year period, both new and refills. There were 12 diabetes drugs in the category.

10. Lantus: 9.5 million

13. Lantus Solostar: 9.053 million

15. Januvia: 8,746 million

30. Levemir: 4.75 million

35. Novolog: 4.2 million

40. Novolog Flexpen: 3.976 million

43. Humalog: 3.568 million

49. Janumet: 3.26 million

65. Humalog Kwikpen: 2.234 million

73. Onglyza: 1.78 million

77. Victoza: 1.684 million

100. Humulin: 1.217 million

The top prescribed non-diabetes drug was Crestor, with 23.737 million prescriptions.

The Top 10 Overall

The 10 top-selling drugs for the reported sales period were:

1. Abilify: $6.391 billion

2. Nexium: $6.087 billion

3. Cymbalta: $5.432 billion

4. Humira: $5.352 billion

5. Crestor: $5.318 billion

6. Advair Diskus: $5.114 billion

7. Enbrel: $4.673 billion

8. Remicade: $4.058 billion

9. Copaxone: $3.789 billion

10. Neulasta: $3.358 billion

 

Leave a Reply

Your email address will not be published. Required fields are marked *